Figure 3
From: MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition
MiR-129-3p and CP110 are functionally involved in the docetaxel response of breast cancer cells.
(A,B) MDA-MB-231, MDA-MB-231/Doc and MCF-7 cells were transfected with miR-129 or miR-129-3p inhibitor for 48 hrs and then treated with various concentrations of docetaxel for 48 hrs and cell viability was analyzed using MTT assay. (C) MDA-MB-231 cells were transfected with CP110 shRNA or NC for 48 hrs, then treated with various concentrations of docetaxel for 48 hrs and cell viability was assessed using MTT assay. Transfection efficiency was assessed by western blot analysis. (D) Time-dependent effects of miR-129 on the proliferation of MDA-MB-231 and MCF-7 cells were confirmed using MTT assay, following treatment with docetaxel. (E–G) MDA-MB-231/Doc, MDA-MB-231-miR-129 and MCF-7-miR-129 cells were transfected with CP110 or NC for 48 hrs, then various concentrations of docetaxel were added for 48 hrs and cell viability was assessed using MTT assay. Transfection efficiency was assessed by western blot analysis. (H) Time-dependent effects of miR-129 on the proliferation of MDA-MB-231-miR-129 and MCF-7-miR-129 cells were confirmed using MTT assay, following treatment with docetaxel. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t-test.
